Share

March 2021; 8 (2) ArticleOpen Access

Biological Significance of Anti–SARS-CoV-2 Antibodies

Lessons Learned From Progressive Multifocal Leukoencephalopathy

Navid Manouchehri, Lawrence Steinman, Olaf Stuve
First published December 24, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000935
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
504

Share

Article Information

vol. 8 no. 2 e935
DOI: 
https://doi.org/10.1212/NXI.0000000000000935
PubMed: 
33361386
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 13, 2020
  • Accepted in final form November 9, 2020
  • First Published December 24, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Navid Manouchehri, MD (navid.manouchehriardestani{at}utsouthwestern.edu),
    2. Lawrence Steinman, MD (steiny{at}stanford.edu) and
    3. Olaf Stuve, MD, PhD
  1. Navid Manouchehri, MD (navid.manouchehriardestani{at}utsouthwestern.edu),
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Lawrence Steinman, MD (steiny{at}stanford.edu) and
    3. Scientific Advisory Boards:

    1. Novartis, Atreca, Tolerion, Teva, AbbVie, Bristol Myers Squibb, Gossamer, 180LS, TG Therapeutics, Atara Bio

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Novartis, Atara Bio

    Editorial Boards:

    1. MS Journal, Proceedings National Academy of Sciences

    Patents:

    1. I have a patent pending on cytokines and type 1 interferons. I have multiple patents on antigen specific tolerance.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Commercial Novartis, Atreca, Tolerion, Teva, AbbVie, Bristol Myers Squibb, Gossamer, 180LS, TG Therapeutics, Atara Bio

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Atara Bio, Novartis

    Research Support, Government Entities:

    1. NIH 2U01AI101984-06 Cooperative Study Group for Autoimmune Disease Prevention (U01)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Stock options and board membership in Tolerion, Atreca Board of Directors BioAtla

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Tolerion Stock/Stock Options, Medical Equipment & Materials: Tolerion, Atreca, Adaptive

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Olaf Stuve, MD, PhD
    4. Scientific Advisory Boards:

    1. TG Therapeutics, Genentech-Roche, EMD Serono, Celgene, Genzyme

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Therapeutic Advances in Neurological Disorders

    Patents:

    1. PCT/US2019/020380

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Celgene EMD Serono Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Sanofi Genzyme, EMD Serono

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.
  1. Correspondence
    Dr. Stuve olaf.stuve{at}utsouthwestern.edu
View Full Text

Article usage

Article usage: December 2020 to March 2021

AbstractFullPdfSource
Dec 20205732964Highwire
Jan 202152614177Highwire
Feb 202159276118Highwire
Mar 2021273601145Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement